Orexo (DB:C5G) - Stock Price, News & Analysis

C5G Stock Overview

Orexo AB (publ), empresa farmacéutica especializada, desarrolla y comercializa productos farmacéuticos y terapias digitales en Estados Unidos, la Unión Europea e internacionalmente.

About the company

C5G fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Cotiza un 96.4% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 75.14%

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

No tiene una capitalización bursátil significativa (€547M)

Orexo AB (publ) Competitors

Apontis Pharma

XTRA:APPH

€58.6m

SynBiotic

DUSE:SBX

€51.0m

MPH Health Care

DB:93M1

€93.3m

Biofrontera

XTRA:B8F

€21.4m

Price History & Performance

Summary of all time highs, changes and price drops for Orexo
Historical stock prices
Current Share Price	kr1.36
52 Week High	kr1.61
52 Week Low	kr0.70
Beta	0.58
1 Month Change	-3.40%
3 Month Change	3.97%
1 Year Change	14.45%
3 Year Change	-69.20%
5 Year Change	-81.21%
Change since IPO	-76.74%

Recent updates

Shareholder Returns

	C5G	DE Pharmaceuticals	DE Market
7D	12.2%	-3.3%	-0.03%
1Y	14.5%	-29.5%	5.5%

Rentabilidad frente al sector: C5G superó al sector German Pharmaceuticals , que obtuvo un rendimiento del -30.7% el año pasado.

Rentabilidad vs. Mercado: C5G superó al mercado German, que obtuvo un rendimiento del 4.1% el año pasado.

Price Volatility

Is C5G's price volatile compared to industry and market?
C5G volatility
C5G Average Weekly Movement	5.8%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: C5G no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: C5GLa volatilidad semanal ha disminuido de 15% a 6% en el último año.

About the Company

Founded	Employees	CEO	Website
1994	116	Nikolaj Sorensen	https://www.orexo.com

Orexo AB (publ), empresa farmacéutica especializada, desarrolla y comercializa productos farmacéuticos y terapias digitales en Estados Unidos, la Unión Europea e internacionalmente. Sus productos incluyen comprimidos de Zubsolv para el tratamiento del trastorno por consumo de opiáceos; Abstral para el tratamiento del dolor irruptivo en pacientes con cáncer; y Edluar para el tratamiento del insomnio. La empresa está desarrollando OX124 para la sobredosis de opiáceos; OX125 para la medicación de rescate y la sobredosis de opiáceos; OX640 para el tratamiento de urgencia de reacciones alérgicas; y OX-MPI para el tratamiento de la endometriosis.

Orexo AB (publ) Fundamentals Summary

How do Orexo's earnings and revenue compare to its market cap?
C5G fundamental statistics
Market cap	€48.06m
Earnings (TTM)	-€11.12m
Revenue (TTM)	€55.36m

0.9x

P/S Ratio

-4.3x

P/E Ratio

Is C5G overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C5G income statement (TTM)
Revenue	kr638.80m
Cost of Revenue	kr88.90m
Gross Profit	kr549.90m
Other Expenses	kr678.20m
Earnings	-kr128.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 08, 2024

Earnings per share (EPS)	-3.72
Gross Margin	86.08%
Net Profit Margin	-20.08%
Debt/Equity Ratio	761.3%

How did C5G perform over the long term?

See historical performance and comparison

C5G Stock Overview

Rewards

Risk Analysis

Orexo AB (publ) Competitors

XTRA:APPH

€58.6m

DUSE:SBX

€51.0m

DB:93M1

€93.3m

XTRA:B8F

€21.4m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (Publ) Announces Board Resignations

New major risk - Financial position

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Recent updates

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (Publ) Announces Board Resignations

New major risk - Financial position

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

No longer forecast to breakeven

Third quarter 2023 earnings released

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

Second quarter 2023 earnings released

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

First quarter 2022 earnings released

Orexo AB (publ) Announces Board Appointments

Full year 2021 earnings released: kr6.51 loss per share (vs kr2.45 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought €10k worth of stock

Independent Director recently bought €10k worth of stock

Independent Chairman of the Board recently bought €40k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

New 90-day low: €4.25

President & CEO recently bought €7.5k worth of stock

Orexo AB (publ) to Report Q3, 2021 Results on Nov 03, 2021

Orexo Starts to Test modiaT on Patients in Collaboration with Apexb.Io and Magellan Rx Management

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

Revenue beats expectations

Orexo Strengthens IP Rights for Overdose Rescue Drug OX124

New 90-day high: €5.24

Orexo AB Enters into License and Supply Agreement with Accord Healthcare for ZUBSOLV

Revenue misses expectations

Orexo AB (Publ) Reaffirms Earnings Guidance for the Year of 2020

Orexo AB (publ) to Report Q1, 2021 Results on Apr 29, 2021